Literature DB >> 24688778

Radiation dose effect in locally advanced non-small cell lung cancer.

Feng-Ming Spring Kong1, Jing Zhao1, Jingbo Wang1, Corrine Faivre-Finn1.   

Abstract

Radiation is the foundation of treatment for locally advanced non-small cell lung cancer (NSCLC), and as such, optimal radiation dose is essential for successful treatment. This article will briefly review biological considerations of radiation dose and their effect in the context of three-dimensional conformal radiation therapy (3D-CRT) including intensity modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) for NSCLC. It will focus on literature review and discussions regarding radiation dose effect in locally advanced NSCLC including potential severe and lethal toxicities of high dose radiation given with concurrent chemotherapy. Potential new approaches for delivering safe and effective doses by individualizing treatment based on functional imaging are being applied in studies such as the PET boost trial and RTOG1106. The RTOG concept of delivering high dose radiation to the more resistant tumors with the use of isotoxic dose prescription and adaptive planning will also be discussed in detail.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); concurrent chemotherapy; radiation dose

Year:  2014        PMID: 24688778      PMCID: PMC3968556          DOI: 10.3978/j.issn.2072-1439.2014.01.23

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  74 in total

1.  A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.

Authors:  T Berghmans; P Van Houtte; M Paesmans; V Giner; J Lecomte; G Koumakis; M Richez; S Holbrechts; M Roelandts; A P Meert; S Alard; N Leclercq; J P Sculier
Journal:  Lung Cancer       Date:  2008-09-19       Impact factor: 5.705

2.  Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.

Authors:  Chandra P Belani; Hak Choy; Phil Bonomi; Charles Scott; Patrick Travis; John Haluschak; Walter J Curran
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

3.  Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.

Authors:  Erik C J Phernambucq; Koen J Hartemink; Egbert F Smit; Marinus A Paul; Pieter E Postmus; Emile F I Comans; Suresh Senan
Journal:  J Thorac Oncol       Date:  2012-08       Impact factor: 15.609

4.  First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy.

Authors:  José S A Belderbos; Katrien De Jaeger; Wilma D Heemsbergen; Yvette Seppenwoolde; Paul Baas; Liesbeth J Boersma; Joos V Lebesque
Journal:  Radiother Oncol       Date:  2003-02       Impact factor: 6.280

5.  Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary?

Authors:  Kuai-le Zhao; Jin-bo Ma; Guang Liu; Kai-liang Wu; Xue-hui Shi; Guo-liang Jiang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-12-11       Impact factor: 7.038

6.  Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer.

Authors:  Ramesh Rengan; Kenneth E Rosenzweig; Ennapadam Venkatraman; Lawrence A Koutcher; Jana L Fox; Reena Nayak; Howard Amols; Ellen Yorke; Andrew Jackson; C Clifton Ling; Steven A Leibel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-01       Impact factor: 7.038

7.  A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.

Authors:  Shuanghu Yuan; Xindong Sun; Minghuan Li; Jinming Yu; Ruimei Ren; Yonghu Yu; Jianbin Li; Xiuqing Liu; Renben Wang; Baosheng Li; Li Kong; Yong Yin
Journal:  Am J Clin Oncol       Date:  2007-06       Impact factor: 2.339

8.  A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.

Authors:  Feng-Ming Spring Kong; Kirk A Frey; Leslie E Quint; Randall K Ten Haken; James A Hayman; Marc Kessler; Indrin J Chetty; Daniel Normolle; Avraham Eisbruch; Theodore S Lawrence
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544

9.  Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.

Authors:  Mattia Falchetto Osti; Linda Agolli; Maurizio Valeriani; Teresa Falco; Stefano Bracci; Vitaliana De Sanctis; Riccardo Maurizi Enrici
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-20       Impact factor: 7.038

10.  Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with Non-Small Cell Lung Cancer.

Authors:  Apollonia L J Uitterhoeve; Mia G J Koolen; Rob M van Os; Kees Koedooder; Marlou van de Kar; Bradley R Pieters; Caro C E Koning
Journal:  Radiat Oncol       Date:  2007-07-23       Impact factor: 3.481

View more
  22 in total

1.  Gefitinib induces non-small cell lung cancer H1650 cell apoptosis through downregulating tumor necrosis factor-related apoptosis-inducing ligand expression levels.

Authors:  Hanjie Yi; Shanfeng Li; Hui Li; Peng Wang; Hongyu Zheng; Xiaochun Cheng
Journal:  Oncol Lett       Date:  2018-07-17       Impact factor: 2.967

2.  A multiobjective Bayesian networks approach for joint prediction of tumor local control and radiation pneumonitis in nonsmall-cell lung cancer (NSCLC) for response-adapted radiotherapy.

Authors:  Yi Luo; Daniel L McShan; Martha M Matuszak; Dipankar Ray; Theodore S Lawrence; Shruti Jolly; Feng-Ming Kong; Randall K Ten Haken; Issam El Naqa
Journal:  Med Phys       Date:  2018-06-04       Impact factor: 4.071

3.  Evaluation of adaptive treatment planning for patients with non-small cell lung cancer.

Authors:  Hualiang Zhong; Salim M Siddiqui; Benjamin Movsas; Indrin J Chetty
Journal:  Phys Med Biol       Date:  2017-01-10       Impact factor: 3.609

4.  Development of a Fully Cross-Validated Bayesian Network Approach for Local Control Prediction in Lung Cancer.

Authors:  Yi Luo; Daniel McShan; Dipankar Ray; Martha Matuszak; Shruti Jolly; Theodore Lawrence; Feng Ming Kong; Randall Ten Haken; Issam El Naqa
Journal:  IEEE Trans Radiat Plasma Med Sci       Date:  2018-05-02

5.  Accelerated hypofractionated radiotherapy with concomitant chemotherapy in locally advanced squamous cell carcinoma of lung: evaluation of response, survival, toxicity and quality of life from a Phase II randomized study.

Authors:  Soumyajit Roy; Sushmita Pathy; Bidhu K Mohanti; Vinod Raina; Anand Jaiswal; Rakesh Kumar; Mani Kalaivani
Journal:  Br J Radiol       Date:  2016-03-17       Impact factor: 3.039

Review 6.  Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.

Authors:  Liangliang Xu; Chang Zou; Shanshan Zhang; Timothy Shun Man Chu; Yan Zhang; Weiwei Chen; Caining Zhao; Li Yang; Zhiyuan Xu; Shaowei Dong; Hao Yu; Bo Li; Xinyuan Guan; Yuzhu Hou; Feng-Ming Kong
Journal:  J Hematol Oncol       Date:  2022-07-07       Impact factor: 23.168

Review 7.  Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients.

Authors:  L Ceniceros; J Aristu; E Castañón; C Rolfo; J Legaspi; A Olarte; G Valtueña; M Moreno; I Gil-Bazo
Journal:  Clin Transl Oncol       Date:  2015-08-05       Impact factor: 3.405

8.  Intensity-modulated radiotherapy with more than 60 Gy improved the survival of inoperable patients with locally advanced esophageal squamous cell carcinoma: A population-based real-world study.

Authors:  Wei Zhang; Qing Xie; Bifa Zhu; Xiaokang Wang; Ling He; Yong Zhang
Journal:  Medicine (Baltimore)       Date:  2022-04-22       Impact factor: 1.817

9.  Allyl isothiocyanate induces replication-associated DNA damage response in NSCLC cells and sensitizes to ionizing radiation.

Authors:  Kaushlendra Tripathi; Usama K Hussein; Roja Anupalli; Reagan Barnett; Lavanya Bachaboina; Jennifer Scalici; Rodney P Rocconi; Laurie B Owen; Gary A Piazza; Komaraiah Palle
Journal:  Oncotarget       Date:  2015-03-10

10.  The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells.

Authors:  Roberto Gomez-Casal; Chitralekha Bhattacharya; Michael W Epperly; Per H Basse; Hong Wang; Xinhui Wang; David A Proia; Joel S Greenberger; Mark A Socinski; Vera Levina
Journal:  Cancers (Basel)       Date:  2015-05-22       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.